• Radiation Oncology Journal
• /
• v.31 no.2
• /
• pp.66-71
• /
• 2013

Purpose: We evaluated the effectiveness and safety of ipsilateral radiotherapy for the patient with well lateralized tonsil cancer: not cross midline and <1 cm of tumor invasion into the soft palate or base of tongue. Materials and Methods: From 2003 to 2011, twenty patients with well lateralized tonsil cancer underwent ipsilateral radiotherapy. Nineteen patients had T1-T2 tumors, and one patient had T3 tumor; twelve patients had N0-N2a disease and eight patients had N2b disease. Primary surgery followed by radiotherapy was performed in fourteen patients: four of these patients received chemotherapy. Four patients underwent induction chemotherapy followed by concurrent chemoradiotherapy (CCRT). The remaining two patients received induction chemotherapy followed by radiotherapy and definitive CCRT, respectively. No patient underwent radiotherapy alone. We analyzed the pattern of failure and complications. Results: The median follow-up time was 64 months (range, 11 to 106 months) for surviving patients. One patient had local failure at tumor bed. There was no regional failure in contralateral neck, even in N2b disease. At five-year, local progression-free survival, distant metastasis-free survival, and progression-free survival rates were 95%, 100%, and 95%, respectively. One patient with treatment failure died, and the five-year overall survival rate was 95%. Radiation Therapy Oncology Group grade 2 xerostomia was found in one patient at least 6 months after the completion of radiotherapy. Conclusion: Ipsilateral radiotherapy is a reasonable treatment option for well lateralized tonsil cancer. Low rate of chronic xerostomia can be expected by sparing contralateral major salivary glands.

• Radiation Oncology Journal
• /
• v.22 no.2
• /
• pp.106-114
• /
• 2004

Purpose : This study was done to evaluate xerostomia fellowing intensity modulated radiotherapy for patients with head and neck cancer, and to analyze the correlation between the dosimetric parameters and xerostomia parameters. Materials and Methods : From February till October 2003, 13 patients with 3 months of follow-up were evaluated for xerostomia after being treated for head and neck cancer with IMRT. Their median age was 57 years(range: 43$\~$77). Xerostomia were assessed with a 4-question xerostomia questionnaire score (XQS) and a test for salivary flow rates (unstimulated and stimulated). The patients were also given a validated LENT SOMA scale (LSC) questionnaire. The evaluations were completed before radiation therapy (pre-RT) and at 1 and, 3 months after radiation therapy (RT). We evaluated xerostomia at pre-RT, 1 and, 3 months after RT. The association between the xerostomia parameters (XQS and LSC) and salivary flow rates (unstimulated and stimulated: USFR and SSFR) was assessed at 1 and 3 months after RT. Resrlts : All 13 patients showed no significant changes in XQS, LSC and Salivary Flow rates. As a result, we couldn't find out about xerostomia development. Based on the total mean parotid dose, 3,500 cGy, we divided these patients into two groups. The 8 patients (<3,500 cGy) showed no significant changes in XQS, LSC and Salivary Flow rates However, in 5 Patients ($\geq$3,500 cOGy), there was a significant increase in USFR and, SSFR at 3 months after RT, and for the XQS and, LSC at 1 and 3 months after RT. The correlation between XQS and, LSC, and USFR and, SSFR in ail patients (13) was significant at 3 months after RT. The correlation had a tendency to the decrease for USFR and, SSFR in proportion to the increase of XQS and, LSC. Conclusion : Based on the results of this study, IMRT seem to be an effective treatment to significantly decrease the xerostomia. XQS and, LSC seem to be a effective tool for predicting the xerostomia. A total parotid gland mean dose of <3,500 cGy should be a planning goal if substantial sparing of the gland function is desired. Furthermore, patients should be enrolled in a study to define a more accurate threshold dose for the parotid gland.

• Journal of Oral Medicine and Pain
• /
• v.23 no.3
• /
• pp.235-239
• /
• 1998

In Sjogren syndrome, abruptly decreased salivation and delayed lag time reveal that many acini cells are destructed and Lymphocytes infiltration is supposed as the main cause that makes dysfunction of salivation. In this case report, the biopsy of minor salivary glands is very useful diagnostic method of Sjogren's syndrome with sialometry,sialography, salivary gland scan.

• The Journal of Korean Obstetrics and Gynecology
• /
• v.23 no.2
• /
• pp.145-153
• /
• 2010

Purpose: Sjogren's syndrome is a type of autoimmune disease and characterized by the keratoconjunctivitis sicca, xerostomia, dryness of mouth & eyes and rheumatoid arthritis or another connective tissue disease. In the Traditional Korean Medicine, there is few report to diagnose and treat Sjogren's syndrome. Methods: The subject was a typical Sjogren's syndrome in 48-year old women whose complaints were dryness of mouth and eyes, severe general myalgia. The author treated her with acupuncture and herbal medicine therapy, then evaluated with MMQ score, XQS grade and VAS score on a regular basis. Results: After treatment, clinical symptoms were improved, MMQ score and XQS grade were decreased. Conclusion: The Traditional Korean Medical Therapy combined acupuncture with herbal medicine relieves the symptom of Sjogren's syndrome.

• The Journal of Internal Korean Medicine
• /
• v.40 no.2
• /
• pp.262-269
• /
• 2019

Xerostomia is a symptom of subjective complaints due to decreased salivary secretion or various other causes, which is common in about 30% of elderly people. Parasympathetic stimulants or artificial saliva are used as remedies, but this has side effects, and there are limitations in completely resolving symptoms. In this study, an 88-year-old woman with subjective dry mouth syndrome for the previous two to three years was treated with spinal pharmacopuncture and herbal medicine (Yookmigihwang-tang). The patient received pharmacopuncture at the thoracic 3rd, 6th, and 10th level twice a day and took herbal medicine three times daily for seven days. Both the degree of oral dryness and behavior were improved after treatment of Korean medicine, especially in the case of pharmacopuncture for inner core muscles.

• Journal of Oral Medicine and Pain
• /
• v.33 no.1
• /
• pp.67-73
• /
• 2008

To investigate the change of taste sensitivity which follows after treatment for xerostomia, from September, 2006 to July, 2007, we categorized the patients, who were diagnosed as xerostomia in Oral Medicine, College of Dentistry, Busan National University, as subject group and from September, 2007 to December. The patients who were not diagnosed as systemic disease were categorized as control group. The results were as follows ; 1. Taste threshold comparison showed the differences at tongue lateral, tongue tip, circumvallate papilla between subject and control. 2. Taste threshold comparison showed no difference in male between subject and control. 3. Taste threshold comparison showed decrease in whole tongue except soft palate in female. 4. Taste threshold comparison showed no difference between first and second visit, but there was a tendency to change in circumvallate papilla.

• The Korean Journal of Nuclear Medicine
• /
• v.35 no.6
• /
• pp.393-397
• /
• 2001

Surgery, radioiodine therapy, and thyroxine treatment represent established therapeutic measures of proven efficacy for the treatment of well-differentiated thyroid cancer. However, in some cases, dedifferentiation is noted and it makes tumors refractory to conventional treatment. Recently, retinoic acid redifferentiation therapy was evaluated in several in vitro and in vivo studios. We report a patient with papillary carcinoma in whom metastatic lesions became radioiodine negative on high-dose therapy. Redifferentiation therapy with retinoic acid induced radioiodine uptake in some of metastatic tissues. Side effects such as xerostomia and cheilosis were mild. We recommend retinoic acid redifferentiation therapy as an option for the treatment of thyroid cancer with negative radioiodine uptake after high-dose radioiodine therapy.

• The Journal of Internal Korean Medicine
• /
• v.38 no.2
• /
• pp.131-137
• /
• 2017

Black hairy tongue is a benign medical condition, which is characterized by elongated filiform lingual papillae, with a typical carpet-like appearance on the dorsum of the tongue. We describe the case of a 70-year-old Korean female with black hairy tongue, who complained of black hairy tongue accompanied by xerostomia. The patient was treated with Jibaekjihwang-tang-gagambang and electric acupuncture for 13 days. Black hairy tongue was evaluated by its visual appearance and by calculating hue-saturation-brightness (HSB) and red-green-blue (RGB) values of images of the tongue using a photo-edit program. Salivary flow rate (SFR) was evaluated to evaluate oral dryness. After 13 days of treatment, the black fur disappeared, and the brightness and RGB values of the black fur increased. In addition, the SFR increased. We conclude that Korean medicine could be the treatment choice for black hairy tongue.

• The Journal of Internal Korean Medicine
• /
• v.43 no.2
• /
• pp.130-143
• /
• 2022

Objective: This case report presents the effects of traditional Korean medical treatment for a patient with symptoms of the upper burner due to Beçhet's disease. Methods: A 42-year-old male patient was treated with traditional Korean herbal medicine (herbal formulas and patent medicines), acupuncture, and cupping therapy. Neck, ocular, and right wrist pain and xerostomia were assessed daily with a numeric rating scale (NRS) and grading assessment tool for subjective symptoms. Results: For a total of 20 days over two hospitalizations, the patient's neck pain was relieved from NRS 4 to 1, the ocular pain from NRS 5 to 1, the right wrist pain from NRS 7 to 1, and the xerostomia from grade 8 to 1. Conclusion: These results show that Beçhet's disease symptoms of the upper burner can be relieved with traditional Korean medical treatment, although additional well-designed studies are required to confirm these findings.

• Journal of Oral Medicine and Pain
• /
• v.19 no.2
• /
• pp.25-45
• /
• 1994

The purposes of this study were to investigate the effect of pilocarpine-containing chewing gum for the treatment of xerostomia and to compare the effect of pilocarpine-containing chewing gum with that of pilocarpine oral administration. The 20 subjective and objective xerostomic patients were included in this study and divided into 3 groups. Five subjects were included in gum base chewing group, 10 in pilocarpine-containing gum chewing, and 5 in pilocarpine oral administration. The author measured unstimulated whole salivary flow rate, stimulated parotid salivary flow rate, pH of resting whole saliva, viscosity of stimulated whole saliva, and subjective symptoms and discomforts using VAS(visual analogue scale) at the beginning of the experiment. And the author investigated the changes of these factors at 1, 2, 3, and 4 week after. The obtained results were as follows : 1. There were significant increases in the unstimulated whole salivary flow rate in pilocarpine-containing gum chewing and pilocarpine oral administration groups. But there was no significant difference between pilocarpine-containing gum chewing and pilocarpine oral administration groups. 2. There was a significant increase in the stimulated parotid salivary flow rate in pilocarpine- containing gum chewing group. But there was no significant difference between pilocarpine- containing gum chewing and pilocarpine oral administration groups. 3. The change of salivary pH showed the increasing pattern in all groups. But there was no significant difference among groups. 4. There were no significant changes in the values of salivary viscosity in all groups through the experimental period. 5. There were significant decreases of VAS(visual analogue scale) in the degree of subjective symptoms and discomforts in pilocarpine-containing gum chewing and pilocarpine oral administration groups. But there was no significant difference between pilocarpine- containing gum chewing and pilocarpine oral administration groups.